StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Autolus Therapeutics (AUTL) Deal with Blackstone Overall Positive - Mizuho
November 8, 2021 1:03 PM
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $18.00 price target on Autolus Therapeutics (NASDAQ ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Autolus Therapeutics (AUTL) Announces Publication Describing its Controllable CAR T Cell System
November 10, 2021 7:06 AM
Autolus Therapeutics (AUTL) Announces $250M Investment from Blackstone (BX) to Advance CAR T Development
November 8, 2021 5:41 AM
Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
November 8, 2021 2:00 AM